ConductScience.org, home

Paper17513820

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.

Hudis CA and 10 others. J Clin Oncol, 2007. Cited by 745 papers, by iCite.

Cite this record

ConductScience Library. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. Papers, record 17513820. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17513820

Download JSON
Disease
breast cancer1,032 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
PubMed
Journal
J Clin Oncol
PubMed
Year
2007
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
745
iCite
Relative citation ratio, by iCite
15.6
iCite
Revised in PubMed
2022-04-09
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hudis CAClifford A
2Barlow WEWilliam E
3Costantino JPJoseph P
4Gray RJRobert J
5Pritchard KIKathleen I
6Chapman JAJudith-Anne W
7Sparano JAJoseph A
8Hunsberger SSally
9Enos RARebecca A
10Gelber RDRichard D
11Zujewski JAJo Anne

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Breast NeoplasmsMajor topic
Chemotherapy, AdjuvantMajor topic
Clinical Trials as TopicMajor topic
Endpoint DeterminationMajor topic
Radiotherapy, AdjuvantMajor topic
Carcinoma, Ductal, Breast
Carcinoma, Intraductal, Noninfiltrating
Carcinoma, Lobular
Female
Humans
Neoplasm Invasiveness
Neoplasm Recurrence, Local
Survival Rate

Source PubMed

Download CSV of topics

Trials4

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT03078751Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast CancerResultsClinicalTrials.gov
NCT03081234Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast CancerResultsClinicalTrials.gov
NCT06412211A Clinical Feasibility Study of a Photoacoustic FinderBackgroundClinicalTrials.gov
NCT07220135Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast CancerBackgroundClinicalTrials.gov

Download CSV of trials

Cited by451

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 745 citations.

PMIDTitleJournalYearIn PapersSource
42923147Practical guidance for collecting reproducible time-to-event endpoints in retrospective observational oncology studies.Front Epidemiol2026https://conductscience.org/library/papers/42923147PubMed
42636977Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial.Ann Oncol2026https://conductscience.org/library/papers/42636977PubMed
42636438Tumour-infiltrating lymphocytes differ across MammaPrint® classifications in breast cancer.Endocr Relat Cancer2026https://conductscience.org/library/papers/42636438PubMed
42557562The tumour microenvironment influences long-term tamoxifen benefit in postmenopausal ER+/HER2- breast cancer patients: a secondary analysis of the randomised Stockholm Tamoxifen (STO-3) trial.BMC Med2026https://conductscience.org/library/papers/42557562PubMed
42499497Rapid relapse in triple-negative breast cancer: clinical patterns, platinum resistance, and implications for clonal evolution.Front Pharmacol2026https://conductscience.org/library/papers/42499497PubMed
42490883A study on the prognostic assessment of triple-negative breast cancer using habitat analysis of preoperative DCE-MRI subtraction maps.Front Oncol2026https://conductscience.org/library/papers/42490883PubMed
42438913Prognostic analysis according to adjuvant chemotherapy and anti-HER2 therapy following surgery in T1a/b HER2-positive breast cancer.Korean J Intern Med2026https://conductscience.org/library/papers/42438913PubMed
42384406Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial.JAMA Surg2026https://conductscience.org/library/papers/42384406PubMed
42214557Updated results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) trial.Ann Oncol2026https://conductscience.org/library/papers/42214557PubMed
42114027Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial.J Clin Oncol2026https://conductscience.org/library/papers/42114027PubMed
41918082Prognostic value of pre-treatment serum CA19-9 and lymphocyte-to-monocyte ratio in HR+/HER2- breast cancer: a retrospective cohort study.BMC Cancer2026https://conductscience.org/library/papers/41918082PubMed
41832961Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer.JNCI Cancer Spectr2026https://conductscience.org/library/papers/41832961PubMed
41774182
Identifying hormone receptor-positive breast cancer subtypes with recurrence scores derived from pathological data without Ki-67 indices: a clinicopathological study of breast cancer survival in West Asia.
Virchows Arch2026https://conductscience.org/library/papers/41774182PubMed
41712503Tamoxifen therapy benefit in luminal A and B breast cancer with 20-year follow-up.J Natl Cancer Inst2026https://conductscience.org/library/papers/41712503PubMed
41699108Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer.Commun Med (Lond)2026https://conductscience.org/library/papers/41699108PubMed
41652501Prognostic value of metastatic lymph-node ratio and log-odds of positive nodes after neoadjuvant chemotherapy in breast cancer.World J Surg Oncol2026https://conductscience.org/library/papers/41652501PubMed
41593108Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial.NPJ Breast Cancer2026https://conductscience.org/library/papers/41593108PubMed
41462298Circulating T-cell receptor repertoire and clinicopathological correlations in breast cancer patients: immune repertoire analysis from the VGH-TAYLOR study.Breast Cancer Res2025https://conductscience.org/library/papers/41462298PubMed
41318535Pregnancy-associated breast cancer: gestational weight gain impact and nomogram validation.BMC Cancer2025https://conductscience.org/library/papers/41318535PubMed
41313969Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX).ESMO Open2025https://conductscience.org/library/papers/41313969PubMed

See all 451 cited byDownload CSV of cited by

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
RIBOCICLIBCHEMBL3545110Results2https://conductscience.org/library/drugs/CHEMBL3545110

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17513820

GET https://conductscience.org/api/papers/v1/17513820/cited_by?page=2